The pharmaceutical industry is experiencing change in ways it hasn’t ever before. On the demand side, we are seeing an aging population, increased prevalence of “Western” diseases, and a dramatic growth in global access to pharmaceuticals. On the supply side, we are seeing increased competition from emerging market players, and a shift in the way drugs are being developed, manufactured, and delivered. Meanwhile, policy makers are struggling with an inherent conflict between desire to provide improved access to better medicines and the need to curb the growth of healthcare expenditures.
One topic at the center of all of these changes is the U.S. biosimilars market. Biosimilar products will offer competition to some of the most expensive drugs on the market, but also require high investment. The promise of biosimilars in the U.S. is to provide cost savings, increase patient access, and promote innovation. And despite being a market still void of any entrants, the U.S. biosimilars market continues to attract attention.
The release of An Outlook on U.S. Biosimilar Competition report from the Thomson Reuters IP & Science provides a comprehensive view of the challenges facing companies entering the United States biosimilar market, and the key players predicted to break into this developing pharmaceutical space. The report examines the scientific and quality considerations within the U.S. FDA’s guidance document, as well as exclusivity policies, clinical trial experience, and global regulations to identify the challenges pharmaceutical companies face in establishing a U.S. market for biosimilar drugs.
Congratulations to Frank Schilder, Research Manager, Research & Development and Blake Howald, Research Scientist, Research & Development, winners of the 2012 Thomson Reuters Inventor Award for their patent, Systems and Methods for Natural Language Generation. Their patent was selected from among all patents filed by Thomson Reuters in 2012.
15 May 2013Thomson Reuters
What is the Inventor Awards program?
The annual Thomson Reuters Inventor Awards program recognizes and rewards employees who have submitted patent applications during the past year. Patents are critical to protecting Thomson Reuters intellectual property, including technology solutions and improvements to products or processes.
Multiple myeloma is the second most common hematological cancer worldwide, with an estimated 22,000 new cases and over 10,000 deaths expected in the U.S. in 2013 and an approximately equivalent incidence in Europe. As increasing age (> 65 years) is a risk factor for the disease, the incidence of multiple myeloma is expected to rise along with increasing life expectancies.
Historically, multiple myeloma was associated with a median survival of just seven months. With the advent of chemotherapeutic drugs such as melphalan in the 1960s, and later high dose chemotherapy and autologous stem cell transplant, newer treatment options resulted in improved median survival times of two to three years. However, while undoubtedly a valuable improvement for patients, the five-year survival rate only increased by nine percentage points over a 30-year period, from 25 percent in 1975 to just 34 percent in 2003.
Our global conference coverage team is made up of scientific specialists and industry professionals. They understand you want comprehensive coverage and you want it now. Which is why we promise to deliver full reports within 28 days of a conference ending — but average 14. Be the first to act on the latest drug pipeline and patents information — with broad conference coverage from Cortellis for Competitive Intelligence.
Neurofibromatosis (NF) causes tumors to grow on nerves throughout the body and can lead to blindness, bone abnormalities, cancer, deafness, disfigurement, learning disabilities, and excruciating and disabling pain. There is currently no known cure and there are relatively few treatment options.
Authorities are investigating a letter addressed to President Barack Obama after the contents tested positive for ricin. The FBI said the envelope was received at a mail screening facility outside the White House and was immediately quarantined. Today’s graphic has everything you need to know about the deadly poision ricin.
What does opportunity look like? Across the industries we serve, we help our customers identify the fundamental forces and changes that affect their worlds.The following story from our 2012 Annual Report uses the power of data visualization to simplify and unify complex sets of data, and illustrate the ways in which the ability to see and understand change can reveal powerful opportunities. (more…)
An in-house attorney for drug manufacturer Merck & Co. did not libel a whistle-blower when he wrote to tell the man his complaint was “unfounded,” a Philadelphia federal judge has ruled.
12 Apr 2013Ronald V. Baker
U.S. District Judge Harvey Bartle III of the Eastern District of Pennsylvania held that Merck’s legal director, Thomas Fitzgibbon, did not intend to blacken Leo Gibney’s reputation when he responded to Gibney’s claim that Gibney’s former employer, Evolution Inc., had overbilled Merck.
It’s all over except for the joy of the victor, and the agony of the rest. The University of Louisville may have won this year’s NCAA Men’s Basketball Championship, but in Metrics Mania, a first-of-its-kind competition measuring the research impact of American universities participating in the NCAA college competition, the real winner is the University of California Berkeley. Berkeley narrowly defeated Harvard by one-hundredth of a point in the final face-off of the tournament. So close, Crimson, so close! (more…)
The parents of a Kentucky child who allegedly suffered a series of shocks when her cochlear implant leaked may proceed to trial with negligence and strict liability claims against the device’s manufacturer, a federal judge has ruled.
10 Apr 2013Ronald V. Baker
U.S. District Judge John G. Heyburn II of the Western District of Kentucky held, however, that federal law preempts the parents’ claims for fraud and breach of implied warranty.
17 May 2013
